DFE Pharma Introduces India Center of Excellence

Goal of ‘Closer to the Formulator’ is to offer a more efficient pharma production process

DFE Pharma, a producer and supplier of pharmaceutical excipients, has launched its new Center of Excellence known as “Closer to the Formulator” (C2F) in Hyderabad, India. C2F is intended to help pharma companies shorten the time from a concept to a finished commercial product via expertise in all phases of pharma development.

With “First-time right” formulations, the company notes, they can lead to a reduction in both costs and time of development, which allow for affordable and new medicines to reach more patients.

The services offered by this new state-of-the-art facility are mainly focused on oral solid dosage forms, comprised of all types of pre-registration work, featuring development, scale-up, and technology transfer. Formulation support includes specialized dosage forms, such as orally disintegrating, effervescent, chewable, and sublingual tablets. C2F capabilities also support efficiency projects, including conversion from wet granulation to direct compression. The center also works with active pharmaceutical ingredients (APIs) and can utilize concepts with model APIs.

“DFE Pharma has made a multimillion-euro investment in the new Center of Excellence in Hyderabad.,” Martti Hedman, CEO of DFE Pharma. “Our overall goal is to help the global and Indian pharmaceutical industry to launch new products fast, at a low cost, and always first-time-right.”